TABLE 3.
Immunosuppression dosing regimen | Alemtuzumab pretreated |
Conventional immunosuppression |
||
---|---|---|---|---|
HCV+ | HCV− | HCV+ | HCV− | |
Total alive/entered | 27/38 (71.5%) | 37/38 (97%) | 17/26 (65%) | 50/58 (86%) |
Daily multidrug therapy | 2 | 3 | 6 | 17 |
Daily monotherapy | 6 | 10 | 10 | 32 |
Every other day | 10 | 8 | 1 | 0 |
3/wk | 3 | 7 | 0 | 1 |
2/wk | 4 | 4 | 0 | 0 |
1/wk | — | — | 0 | 0 |
Every 2 weeks | 1 | 2 | 0 | 0 |
Off immunosuppression | 1 | 3 | 0 | 0 |